{"name":"Vissum, Instituto Oftalmológico de Alicante","slug":"vissum-instituto-oftalmol-gico-de-alicante","ticker":"","exchange":"","domain":"","description":"Vissum, Instituto Oftalmológico de Alicante is a leading eye care provider and research center focused on advancing ophthalmic treatments and patient care. The institute is known for its expertise in clinical trials and innovative therapies, particularly in the area of PRP autologous treatments.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PRP autologous","genericName":"PRP autologous","slug":"prp-autologous","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"PRP autologous","genericName":"PRP autologous","slug":"prp-autologous","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPZmJaOGw5VTRNS3JTa0NjVFZCODVmWmNtMUp6cXJ1clpxLTlVYkJTZ2lfX3hoVy1rUGlyTTJicEpHMUlockY0N09meVc2eHoxSW5zb192Z3I0Rk9xdFdNNkNCYmFKbmhXSDIybFZtZ3kyQjRJVkROdmJOdWZHTlBfVGRublg1R3dTc2J1OUJxYXBhVUpscFZFVU5CVQ?oc=5","date":"2022-04-30","type":"pipeline","source":"Ophthalmology Times Europe","summary":"Cosmetic iris implants pose high risk of vision loss - Ophthalmology Times Europe","headline":"Cosmetic iris implants pose high risk of vision loss","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}